Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy)

Background and objectives: In Italy, Hepatitis C Virus (HCV) infections are most prevalent in people older than 50 years of age, who often experience multi-morbidities, take co-medications, and have a long history of liver disease. These characteristics could potentially affect tolerability of HCV treatments and adherence in this subgroup. After achievement of sustained virological response (SVR), retention into care is very important both to detect the onset of possible complications and prevent further infections. In this study, SVR rates and retention into care of patients treated with directly acting antivirals (DAAs) of a single-center cohort in Southern Italy were evaluated. Materials and Methods: Patients treated with directly acting antivirals from 2014 to 2018 were included. Patients were stratified by age (i.e., <65 vs. ≥65 years) and by cirrhosis presence (i.e., liver stiffness >14.6 KPa or clinical/ultrasound cirrhosis vs. absence of these criteria). Primary outcome was availability of SVR at Weeks 12–24 after the end of treatment. Inter- and intra-group comparisons were performed along the follow-up for significant laboratory parameters. Results: In total, 212 patients were treated; 184 (87%) obtained SVR after the first treatment course and 4 patients after retreatment. Twenty-two (10.4%) patients were lost to follow-up before assessment of SVR, and two patients died before the end of treatment for liver decompensation. Considering only the first treatment episode, per protocol analysis (i.e., excluding patients lost to follow-up) showed the following rates of SVR: 97% (overall), 97% (older age group), 96% (age group <65 years), 94% (cirrhotics), and 100% (non-cirrhotics). By contrast, at the intention to treat analysis (i.e., patients lost were computed as failures), SVR percentages were significantly lower for patients <65 years of age (80%) and for non-cirrhotics (85%). Conclusions: High rates of SVR were obtained. However, younger patients and those without cirrhosis displayed an apparent high risk of being lost to follow-up. This may have important implications: since those who are lost may transmit HCV in case SVR is not achieved, these subpopulations should receive appropriate counselling during treatment.

[1]  R. Sterling,et al.  Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients with Baseline Cirrhosis or High FIB-4 Scores. , 2019, Gastroenterology.

[2]  M. Pistello,et al.  Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases. , 2019, The new microbiologica.

[3]  M. Monami,et al.  Direct‐acting antivirals for HCV treatment in older patients: A systematic review and meta‐analysis , 2019, Journal of viral hepatitis.

[4]  Todd A. Lee,et al.  Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist–Driven Model , 2019, Open forum infectious diseases.

[5]  I. Gentile,et al.  Efficacy of the "first wave" Direct Acting antivirals against HCV infection: results from the Italian LINA (Liver Network Activity) cohort. , 2019, The new microbiologica.

[6]  C. Indolfi,et al.  Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients , 2018, BMC Infectious Diseases.

[7]  G. Giannelli,et al.  Liver Angiopoietin‐2 Is a Key Predictor of D e N ovo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct‐Acting Antivirals , 2018, Hepatology.

[8]  K. Childs,et al.  Efficacy and Tolerability of Direct‐Acting Antivirals for Hepatitis C in Older Adults , 2018, Journal of the American Geriatrics Society.

[9]  E. Asante-Appiah,et al.  Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial , 2018, Hepatology.

[10]  B. Bacon,et al.  Real‐world use of elbasvir‐grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network , 2018, Alimentary pharmacology & therapeutics.

[11]  G. Coppolino,et al.  Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals , 2018, Clinical and molecular hepatology.

[12]  M. Massari,et al.  Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study , 2018, PloS one.

[13]  R. Stauber,et al.  Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus , 2017, Wiener Klinische Wochenschrift.

[14]  A. Shlomai,et al.  AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[15]  T. Asselah,et al.  Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension , 2017, Journal of viral hepatitis.

[16]  B. Bacon,et al.  Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients , 2017, Alimentary pharmacology & therapeutics.

[17]  P. Pafundi,et al.  Electrophysiological Adverse Effects of Direct Acting Antivirals in Patients With Chronic Hepatitis C , 2017, Journal of clinical pharmacology.

[18]  M. Massari,et al.  Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study , 2017, PloS one.

[19]  B. Bacon,et al.  Real‐world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study , 2017, Journal of viral hepatitis.

[20]  S. Zeuzem,et al.  The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection , 2016, Alimentary pharmacology & therapeutics.

[21]  N. Terrault,et al.  Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[22]  A. Walker,et al.  Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.

[23]  D. Samuel,et al.  Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. , 2015, Gastroenterology.

[24]  M. Manns,et al.  Extrahepatic morbidity and mortality of chronic hepatitis C. , 2015, Gastroenterology.

[25]  G. Foti,et al.  Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology) , 2012, BMC Infectious Diseases.

[26]  S. Pol,et al.  FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.

[27]  M. Campbell,et al.  Noninvasive Assessment of Liver Fibrosis by Measurement of Stiffness in Patients With Chronic Hepatitis C , 2006 .